Modulation of the intrinsic antiviral activity by Escherichia coli endotoxin in macrophages from patients with neoplasia.
Macrophages from patients with breast cancer showed an impairment of their antiviral activity. The capability to hinder herpes simplex virus type 2 replication of macrophages from healthy donors and from patients with breast cancer was compared to the in-vitro treatment with Escherichia coli lipopolysaccharide (LPS). The LPS showed a dose-dependent effect on the different macrophage populations studied. Nevertheless, macrophages from healthy donors appeared to be more sensitive to LPS in comparison with macrophages from the patients under our observation. On these cells LPS treatment was not able to modify the antiviral property, when these macrophages were differentiated in autologous serum.